Home > Blog > Ras is no longer undruggable

3 min read

ASCO 2026: RAS Is No Longer Undruggable

For decades, oncologists and drug developers shared an undeniable truth: KRAS – one of the most commonly mutated genes in human cancer – was untargetable. Mutations in KRAS drive approximately 25% of all cancers, including most pancreatic adenocarcinomas, roughly 40% of colorectal cancers, and about 30% of non-small cell lung cancers. For years, despite enormous efforts in clinical research and financial investments, every attempt to inhibit RAS directly had failed. The protein was labelled "undruggable," and the field largely accepted the verdict.

Why Was RAS So Difficult to Target?

RAS proteins function as molecular switches, cycling between an active GTP-bound state and an inactive GDP-bound state. In normal cells, this cycling is tightly regulated. In cancer, mutations – most commonly at codons 12, 13, and 61 – lock RAS in its active, GTP-bound conformation, driving continuous proliferation signaling through the MAPK and PI3K pathways.

The challenge was fundamentally structural. Unlike kinases, RAS offered no deep binding pocket for small molecules to exploit. Its surface appeared smooth and featureless, and GTP bound with picomolar affinity. For years, the target seemed impossible.

The Breakthrough: G12C and the Allosteric Revolution

The paradigm shifted when a cysteine residue unique to the KRAS G12C mutant was identified – this cysteine residue is present in approximately 13% of NSCLC and 3% of CRC, but not in normal KRAS. This cysteine could be covalently locked in the GDP-bound inactive state. Sotorasib (AMG 510) became the first approved KRAS inhibitor in 2021, followed by adagrasib – both specific to the G12C allele. Their approval was historic, but the limitation was obvious: G12C represents only a fraction of KRAS-mutant cancers. KRAS G12D – the dominant mutation in pancreatic cancer – remained untouched.

ASCO 2026: The RASolute 302 Trial Changes Everything

The headline result of ASCO 2026 was daraxonrasib, a RAS(ON) multi-selective inhibitor – a new class that targets multiple active KRAS mutant alleles simultaneously, not just G12C. The Phase 3 RASolute 302 trial evaluated oral daraxonrasib at 300 mg once daily as a second-line treatment for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), versus investigator's choice of standard-of-care cytotoxic chemotherapy (gemcitabine/nab-paclitaxel, mFOLFIRINOX, nanoliposomal irinotecan plus 5-FU, or FOLFOX).

The results were among the most notable data presented at the meeting: overall survival of 13.2 versus 6.6 months (HR 0.40; p<0.0001), a 60% reduction in death risk. PFS improved from 3.5 to 7.3 months (HR 0.45) in the RAS G12 population. The confirmed overall response rate was 33.2% versus 11.8% – nearly tripling the response rate compared to chemotherapy. For context: pancreatic cancer has seen minimal OS improvement in the second line setting over the past decade. A hazard ratio of 0.40 is extraordinary in this disease.

Not Just More Effective - Better Tolerated

What makes the RASolute 302 results particularly compelling is that the survival benefit came with a meaningfully better safety profile. Grade 3 or higher treatment related adverse events occurred in 43.6% of patients receiving daraxonrasib, compared to 57.5% in the chemotherapy arms. Treatment discontinuation due to side effects was 1.2% with daraxonrasib versus 11.2% with chemotherapy. In a patient population that has already been through first-line treatment for one of the most aggressive malignancies in oncology, this tolerability advantage is not a minor footnote – it is clinically and humanly significant.

What Is a RAS(ON) Multi-Selective Inhibitor?

Unlike the G12C-specific covalent inhibitors, RAS(ON) inhibitors target the active (GTP-bound, or "ON") state of multiple RAS mutant alleles. This is possible because structural biology advances revealed that the oncogenic RAS mutants share conformational features in their active state that are distinct from wild-type RAS – creating a therapeutic window. Daraxonrasib and related molecules exploit this difference by targeting active RAS signaling and disrupting interactions with downstream effectors. Daraxonrasib is active across a broad range of common RAS variants, including G12D, G12V and G12R and other alleles that collectively account for most KRAS-driven cancers.

Notably, the trial also included patients without an identified tumor RAS mutation – and the OS benefit was consistent across both the RAS G12 mutant and the overall intent-to-treat populations. This suggests that RAS(ON) signaling may drive PDAC biology even in the absence of a canonical mutation, a finding with significant implications for how we define patient eligibility in future trials.

The Broader Implications

If approved, daraxonrasib and the broader RAS(ON) class could represent a true inflection point.

First, it validates pancreatic cancer as targetable with precision therapy for the first time at scale. Second, it opens the door to clinical programs in KRAS-mutant colorectal, endometrial, biliary, and other cancers where G12D and G12V dominate. Third, it creates a new combination framework – RAS inhibition with chemotherapy, immunotherapy, and downstream MAPK pathway agents – that will drive the next generation of clinical trial design.

For patients, these findings represent a level of optimism that has rarely been seen in pancreatic cancer. Although significant challenges remain, the magnitude of benefit observed in RASolute 302 offers a meaningful signal that the treatment landscape may finally be changing. These results bring hope, and the standing ovations received during the ASCO Plenary show the incredible enthusiasm the oncology community felt when Dr. Brian Wolpin, MD, MHP of Dana-Farber Cancer Institute presented the data.

The tools now exist. The clinical precedent has been established. For a target once considered impossible to drug, the field has clearly entered a new phase.

2 min read

Connect with Veristat at DIA 2026

Jun 5, 2026  Veristat Events

June 14-18, 2026 – Philadelphia, PA

Veristat is excited to join industry leaders and innovators at the DIA 2026 Global...

2 min read

Meet Veristat at the ASCO Annual Meeting

May 5, 2026  Veristat Events

May 29 - June 2, 2026 | Chicago, IL

▶️ At the Forefront of Oncology Progress 

Veristat is pleased to attend the ASCO...